'Unprecedented' Survival Seen With Maintenance Tarlatamab for SCLC in Early Study

(MedPage Today) — The combination of tarlatamab (Imdelltra) and a PD-L1 inhibitor after first-line chemo-immunotherapy showed promise as a maintenance therapy in patients with extensive-stage small cell lung cancer (ES-SCLC), with a manageable…

Source link : https://www.medpagetoday.com/meetingcoverage/iaslc/117402

Author :

Publish date : 2025-09-10 18:32:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
		1	2	3	4	5
6	7	8	9	10	11	12
13	14	15	16	17	18	19
20	21	22	23	24	25	26
27	28	29	30	31

‘Unprecedented’ Survival Seen With Maintenance Tarlatamab for SCLC in Early Study

Large Physician Group Call for RFK Jr.’s Removal

Bispecific Antibody Improves PFS in EGFR-Mutated Lung Cancer

Related Posts

JAK Inhibitor Stays Effective Beyond 1 Year for Giant Cell Arteritis

‘If That Doesn’t Blow Your Mind’: What We Heard This Week

Tirzepatide-Hormone Therapy Combo Tied to Weight Loss in Postmenopausal Women

Prevention Has a Branding Problem

Pool Data Back Safety of Newly Approved Non-Hormonal Treatment for Hot Flashes

What Vaccine Was Tied to Longer Cancer Survival?

JAK Inhibitor Stays Effective Beyond 1 Year for Giant Cell Arteritis

‘If That Doesn’t Blow Your Mind’: What We Heard This Week

Tirzepatide-Hormone Therapy Combo Tied to Weight Loss in Postmenopausal Women

Prevention Has a Branding Problem

Pool Data Back Safety of Newly Approved Non-Hormonal Treatment for Hot Flashes

What Vaccine Was Tied to Longer Cancer Survival?

PFAS Exposure and Brain Development; Food Insecurity and Blood Pressure

ACOG President: Changing Tylenol’s Label Will Drive Baseless Fear

Categories

Archives